Evaluation of autologous adipose-derived mesenchymal stem cell therapy in a patient with acute ischemic cardiomyopathy

Masatatsu Mishima, Xiaolan Liu


Adipose-derived mesenchymal stem cells (AdMSC) is an innovative approach for the treatment of a range of diseases that are not responsive to standard therapies. Their promising role in tissue engineering and ability to modulate the immune system are attractive. AdMSC can differentiate into endothelial cells, myocytes, chondrocytes and osteoblasts. Our aim was to investigate safety and efficacy of intravenous autologous AdMSC in a patient with acute myocardial infarction. AdMSC treatment was associated with improved recovery of the left ventricular function (LVEF), electrocardiographic (ECG) findings and serum BNP level in this patient. AdMSC may be considered to be one of future therapeutic agents for diseases that cannot be cured by conventional therapeutic methods.


Adipose-derived mesenchymal stem cells, autologous, myocardial infarction, cell therapy

Full Text:



Perin EC, HF, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107:2294-2302, 2003.

Perin EC, Silva GAY, Henry TD, et al. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am heart J 161:1078-1087, 2011.

Tse HF, Thambar S, Kwong YL, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery disease (PROTECT-LAD trial). Eur Heart J 28:2998-3005, 2007.

van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 301:1997-2004, 2009.

Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell-based therapy in ischemic heart disease; promise, uncertainties and challenges. Eur Heart J 32:1197-1206, 2011.

Gnecchi M, Danieli P, Cervio E. Mesenchymal stem cells therapy for heart disease. Vascul Pharmacol 57:48-55, 2012.

Hare JM, Traverse JH, Henry TD, et al. A randomized double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54:2277-2286, 2009.

Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogenic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEILON randomized trial. JAMA 308:2369-2379, 2012.

Perin EC, Sanz-Ruiz R, Sánchez PL. et al., Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE Trial. Am Heart J 168:88-95, 2014.

Hirano A, Sano M, Urushihata N, Tanemura H, Oki K, Suzaki E. Assessment of safety and feasibility of human allogeneic adipose-derived mesenchymal stem cells in a

pediatric patient. Ped Res 84:575–577, 2018.

Redfors B, Chen S, Crowley A, et al. B-Type natriuretic peptide assessment in patients undergoing revascularization for left main coronary artery disease. Circulation 138:469-478, 2018.

Zhang L, Tang F, Cai LP, et al. Research on the correlation of urine calcium integrin binding protein-1 and pro-BNP with ischemic heart failure. Eur Rev Med Pharmacol Sci. 2017; 21:4181-4185

Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. Circulation 105:595-601, 2002.

Marrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACICS-TIMI 18. J Am Coll Cardiol 41:1264-1272, 2003.

James SK, Lindbäck J, Tilly J, et al. Troponin and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV sub-study. J Am Coll Cardiol 48:1146-1154, 2006.

Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206-3212, 2004.

Lindahl B, Lindbäck J, Jemberg T, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a fragmin and fast revascularisation during in stability in coronary artery disease (FRISK)-II substudy. J Am Coll Cardiol 45:533-541, 2005.

Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82-91, 1993.

Mizuno Y, Yasue H, Oshima S, et al. Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction. J Card Fail 3:287-293, 1997.

Planat-Bénard V1, Menard C, André M, et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 94: 223-229, 2004.

Suzuki E, Fujita D, Takahashi, et al. Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease. World J Cardiol 7:454-465, 2015.

Nagata H, Li M, Kobayashi E, et al. Cardiac adipose-derived stem cells exhibit high differentiation potential to cardiovascular cells in C57BL/6 mice. Stem cells Transl Med 5:141-151, 2016.

Nakagami H, Maeda K, Morishita R, et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose-derived stromal cells. Arterioscler Thromb Vasc Biol 25:2542-2547, 2005.

Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 109: 656-663, 2004.

Miranville A, Heeschen C, Sengenès C, et al. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 110: 349-355, 2004.

Zhang Y, Yu S, Tuazon JP, et al. Neuroprotective effects of human bone marrow mesenchymal stem cells against cerebral ischemia are mediated in part by an anti-apoptotic mechanism. Neural Regen Res 14:597-604, 2019.

Ikebe C, Suzuki K. Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed Res Int 2014:951512, 2014.

Minteen D, Mahra KG, Rubin JP. Adipose-derived mesenchymal stem cell: biology and potential applications. Adv Biochem Eng Biothchnol 129:59-91, 2013.

De Ugante DA, Morizono K, Elbarbary A, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cell tissues organs 174:110-119, 2003.

Fraser JK, Schreiber R, Strem B, et al. Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes. Nat Clin Pract Cardiovac Med. 2006; 3 (suppl 1): S33-37.

Raedschelders K, Ansley DM, Chen DD. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol Therap 133:230-255, 2012.

Song H, Cha MJ, Song BW, et al. Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex stem cells. Stem Cells 28:555-563, 2012.

Duscher D, Barrera J, Wong VW, et al. Stem cells in wound healing: the future of regenerative medicine? A mini-review. Gerontology. 2016; 62:216-225, 2016.

Aso K, Tsuruhara A, Takagaki K, et al. Adipose-derived mesenchymal stem cells restore impaired mucosal immune responses in aged mice. PLOS ONE. 11:e0148185, 2016.


  • There are currently no refbacks.